The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks
Open accessAbstract
The development of new therapies is an arduous, time-consuming and costly task. Furthermore, the development of many compounds runs into issues related to safety. Drug repurposing, where drugs with established safety in humans are tested and developed for efficacy in a disease other than the one for which they were developed, is gaining traction because of its potential to overcome an initial bottleneck in the drug development process. In “Bedside to Bench,” Stephen Strittmatter discusses the types of scenario in which drug repurposing may be of benefit, such as when a drug is repurposed for a new molecular target or for the same target in a different disease. In “Bench to Bedside,” Michael Pollak focuses on a recent study that suggest that biguanides that are normally used in the treatment of diabetes could have direct cyotoxic action on cancer cells with mutations in respiratory complex I. The pharmacokinetic hurdles that may need to be overcome for this to be translated to the clinic are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518
Phase II and Phase III attrition rates 2011–2012
Arrowsmith, J., & Miller, P. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4090 · Cited by 697
Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aß 42 by Inhibiting Rho
Zhou, Y., Su, Y., Li, B., Liu, F., Ryder, J. W., Wu, X., Gonzalez-DeWhitt, P. A., Gelfanova, V., Hale, J. E., May, P. C., et al. (2003) · Science · doi:10.1126/science.1090154 · Cited by 316
Cited by
GraphDTA: predicting drug–target binding affinity with graph neural networks
Nguyen, T., Le, H., Quinn, T. P., Nguyen, T., Le, T. D., & Venkatesh, S. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa921 · Cited by 1,220
Seyhan, A. A. (2019) · Translational Medicine Communications · doi:10.1186/s41231-019-0050-7 · Cited by 713
Deidda, G., Parrini, M., Naskar, S., Bozarth, I. F., Contestabile, A., & Cancedda, L. (2015) · Nature Medicine · doi:10.1038/nm.3827 · Cited by 268
Drug Repurposing for Viral Infectious Diseases: How Far Are We?
Mercorelli, B., Palù, G., & Loregian, A. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2018.04.004 · Cited by 264
Drug Repurposing: An Effective Tool in Modern Drug Discovery
Kulkarni, V. S., Alagarsamy, V., Solomon, V. R., Jose, P. A., & Murugesan, S. (2023) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023020139 · Cited by 257
Metadata
- Authors
- Strittmatter, S. M.
- Venue
- Nature Medicine
- Published
- 2014-06
- Volume
- 20
- Issue
- 6
- Pages
- 590-591
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1985270532
- Cited by
- 222
- References
- 4
- FWCI
- 12.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks. https://app.cochat.ai/papers/10.1038/nm.3595
- The paper
- Strittmatter, S. M. (2014). Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks. Nature Medicine. https://doi.org/10.1038/nm.3595
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.